Rowan Chapman Acquires Shares of Natera, Inc.

Rowan Chapman, an insider at Natera, Inc. (NasdaqGS: NTRA), purchased 1,674 shares of the company on June 26, 2026. This transaction wasn't part of a pre-planned trading program. The exact value and price of the shares weren't disclosed.

Other Institutional Activity in Natera, Inc.

Several major institutional investors have also been active in Natera, Inc. JPMorgan Chase & Co increased its holdings by 532,333 shares, bringing its total to 13,386,667 shares valued at approximately $2.5 billion, marking a 4.1% increase. Price T Rowe Associates boosted its stake by 1,312,887 shares to 12,184,876 shares, worth about $2.44 billion, a 12.1% increase. BlackRock, Inc. slightly reduced its position by 182,103 shares, now holding 10,677,338 shares valued at $2.14 billion, a 1.7% decrease. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions with holdings of 6,008,496 and 5,644,695 shares, respectively.

Natera, Inc. Stock Down 17.1%

Shares of Natera, Inc. traded near $267.05 on Wednesday. The company has a market cap of approximately $37.5 billion. Although it isn't currently profitable, with a negative forward P/E ratio of -1256.89, its beta of 1.544 indicates higher volatility compared to the market. The stock's 52-week range is between $131.81 and $271.47, with 50-day and 200-day moving averages of $212.40 and $208.58, respectively.

Recent Earnings

Natera, Inc. reported revenue of about $2.5 billion with a growth rate of 38.8%. However, the company posted a net margin of -9.05% and a return on equity of -15.02%. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at Natera, Inc.

Alongside Rowan Chapman, several other insiders made purchases on June 26, 2026. Baynes Roy acquired 1,646 shares, Rubin Eric bought 75 shares, Botha Roelof purchased 1,691 shares, Lynch Thomas Jr. added 1,905 shares, and Marcus Gail Boxer bought 1,669 shares. These transactions were not part of any pre-arranged plans.

Analysts Set New Price Targets

On June 29, 2026, Guggenheim maintained its buy rating on Natera, Inc. with a price target of $290. Bernstein reiterated its buy rating with a target of $310 on June 26, 2026. BTIG and Barclays both maintained buy ratings with targets of $275 and $260, respectively, in late June. The consensus among 21 analysts is a strong buy, with a mean target price of $262.67.

About Natera, Inc.

Natera, Inc. is a healthcare company based in Austin, Texas, specializing in diagnostics and research. It develops and sells molecular testing services globally, including tests for cancer detection, prenatal screening, and organ transplant rejection monitoring. The company, led by CEO Steven Leonard Chapman, employs over 6,100 people and collaborates with various partners to enhance its genetic testing capabilities.

Bottom Line

Rowan Chapman's recent share purchase in Natera, Inc. reflects insider interest in the company. Investors often watch such transactions for insights into management's confidence. Natera's stock has been active, with institutional investors adjusting their holdings and analysts maintaining optimistic ratings. Remember, insider transactions and 13F filings are backward-looking and may not reflect current positions.